Clearside Biomedical’s (CLSD) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. Several other research analysts also recently issued reports on CLSD. HC Wainwright reiterated a “buy” rating and […]
Needham & Company LLC reaffirmed their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. Several other research analysts also recently issued reports on CLSD. HC Wainwright reiterated a “buy” rating and […]
